TY - JOUR
T1 - Colorectal cancer survivorship care plans
T2 - Variations in documentation and posttreatment surveillance recommendations
AU - Chodoff, Alaina
AU - Smith, Katherine C.
AU - Shukla, Aishwarya
AU - Blackford, Amanda L.
AU - Ahuja, Nita
AU - Johnston, Fabian M.
AU - Peairs, Kimberly S.
AU - Ngaiza, Justinian R.
AU - Warczynski, Tam
AU - Nettles, Brenda
AU - Stotsky-Himelfarb, Eden
AU - Murphy, Adrian G.
AU - Mayonado, Nancy
AU - DeSanto, Jennifer
AU - Snyder, Claire F.
AU - Choi, Youngjee
N1 - Funding Information:
Drs. Smith, Snyder, Peairs and Johnston are members of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (P30CA006973). Drs. Youngjee Choi and Kimberly Peairs receive salary support from a Merck Foundation Grant. Dr. Claire Snyder currently receives research support from Pfizer and Genentech and previously received royalties from UptoDate for section authorship related to survivorship. Dr. Nita Ahuja has licensed methylation biomarkers to Cepheid. The other authors declare that they have no conflict of interests.
Funding Information:
The statements in this publication are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors or Methodology Committee. This study was funded by Patient‐Centered Outcomes Research Institute (PCORI) (Award: IHS‐1409‐22534).
Publisher Copyright:
© 2021 Wiley Periodicals LLC.
PY - 2022/3/15
Y1 - 2022/3/15
N2 - Background: Survivorship care plans (SCP) should outline pertinent information about cancer treatment and follow-up. Methods: We descriptively analyzed the content of 74 colorectal cancer SCPs completed as part of a randomized, controlled trial of SCPs at an academic and community cancer center. Surveillance recommendations were compared with American Cancer Society, American Society of Clinical Oncology and National Comprehensive Cancer Network guidelines. Results: SCP information provided in >80% of the plans included participant age, cancer diagnosis, details, and side-effects of treatment (surgery, chemotherapy, radiation) and health promotion recommendations. SCP content documented less frequently included predisposing conditions, genetic counseling/testing information and staging. Posttreatment surveillance recommendations were documented in >90% SCPs. For stage 2–3 cancer, rates of guideline concordant recommendations were 100% for colonoscopy surveillance (Year 1 only), 87% for imaging surveillance, 65% for carcinoembryonic antigen surveillance, and 33% for follow-up visits. Excluding colonoscopy, >15 unique recommendations were listed for each modality across stages and sites, with more variation at the academic site. Conclusions: SCPs consistently recorded information about cancer diagnosis and treatment but omitted critical information about cancer-specific details denoting risk. Surveillance recommendations varied considerably between cancer centers. Future work to improve the consistency of surveillance recommendations documented in SCPs may be needed.
AB - Background: Survivorship care plans (SCP) should outline pertinent information about cancer treatment and follow-up. Methods: We descriptively analyzed the content of 74 colorectal cancer SCPs completed as part of a randomized, controlled trial of SCPs at an academic and community cancer center. Surveillance recommendations were compared with American Cancer Society, American Society of Clinical Oncology and National Comprehensive Cancer Network guidelines. Results: SCP information provided in >80% of the plans included participant age, cancer diagnosis, details, and side-effects of treatment (surgery, chemotherapy, radiation) and health promotion recommendations. SCP content documented less frequently included predisposing conditions, genetic counseling/testing information and staging. Posttreatment surveillance recommendations were documented in >90% SCPs. For stage 2–3 cancer, rates of guideline concordant recommendations were 100% for colonoscopy surveillance (Year 1 only), 87% for imaging surveillance, 65% for carcinoembryonic antigen surveillance, and 33% for follow-up visits. Excluding colonoscopy, >15 unique recommendations were listed for each modality across stages and sites, with more variation at the academic site. Conclusions: SCPs consistently recorded information about cancer diagnosis and treatment but omitted critical information about cancer-specific details denoting risk. Surveillance recommendations varied considerably between cancer centers. Future work to improve the consistency of surveillance recommendations documented in SCPs may be needed.
KW - cancer surveillance
KW - cancer survivorship
KW - colorectal cancer
KW - survivorship care plans
UR - http://www.scopus.com/inward/record.url?scp=85120852853&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85120852853&partnerID=8YFLogxK
U2 - 10.1002/jso.26767
DO - 10.1002/jso.26767
M3 - Article
C2 - 34894361
AN - SCOPUS:85120852853
SN - 0022-4790
VL - 125
SP - 678
EP - 691
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 4
ER -